These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 29803996)

  • 1. SAR studies on truxillic acid mono esters as a new class of antinociceptive agents targeting fatty acid binding proteins.
    Yan S; Elmes MW; Tong S; Hu K; Awwa M; Teng GYH; Jing Y; Freitag M; Gan Q; Clement T; Wei L; Sweeney JM; Joseph OM; Che J; Carbonetti GS; Wang L; Bogdan DM; Falcone J; Smietalo N; Zhou Y; Ralph B; Hsu HC; Li H; Rizzo RC; Deutsch DG; Kaczocha M; Ojima I
    Eur J Med Chem; 2018 Jun; 154():233-252. PubMed ID: 29803996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAR study on Novel truxillic acid monoester-Based inhibitors of fatty acid binding proteins as Next-Generation antinociceptive agents.
    Wang H; Taouil A; Awwa M; Clement T; Zhu C; Kim J; Rendina D; Jayanetti K; Maharaj A; Wang L; Bogdan D; Pepe A; Kaczocha M; Ojima I
    Bioorg Chem; 2022 Dec; 129():106184. PubMed ID: 36244323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Antinociceptive Agent SBFI-26 Binds to Anandamide Transporters FABP5 and FABP7 at Two Different Sites.
    Hsu HC; Tong S; Zhou Y; Elmes MW; Yan S; Kaczocha M; Deutsch DG; Rizzo RC; Ojima I; Li H
    Biochemistry; 2017 Jul; 56(27):3454-3462. PubMed ID: 28632393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugs.
    Berger WT; Ralph BP; Kaczocha M; Sun J; Balius TE; Rizzo RC; Haj-Dahmane S; Ojima I; Deutsch DG
    PLoS One; 2012; 7(12):e50968. PubMed ID: 23236415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Truxillic acid monoamides as fatty acid binding protein 5 inhibitors.
    Zhu C; Schutz L; Jayanetti K; Takemura K; Doswell F; Wang L; Ojima I; Kaczocha M
    Bioorg Med Chem; 2023 Oct; 94():117464. PubMed ID: 37708641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia.
    Kaczocha M; Rebecchi MJ; Ralph BP; Teng YH; Berger WT; Galbavy W; Elmes MW; Glaser ST; Wang L; Rizzo RC; Deutsch DG; Ojima I
    PLoS One; 2014; 9(4):e94200. PubMed ID: 24705380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatty-acid-binding protein inhibition produces analgesic effects through peripheral and central mechanisms.
    Peng X; Studholme K; Kanjiya MP; Luk J; Bogdan D; Elmes MW; Carbonetti G; Tong S; Gary Teng YH; Rizzo RC; Li H; Deutsch DG; Ojima I; Rebecchi MJ; Puopolo M; Kaczocha M
    Mol Pain; 2017 Jan; 13():1744806917697007. PubMed ID: 28326944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatty acid binding protein deletion suppresses inflammatory pain through endocannabinoid/N-acylethanolamine-dependent mechanisms.
    Kaczocha M; Glaser ST; Maher T; Clavin B; Hamilton J; O'Rourke J; Rebecchi M; Puopolo M; Owada Y; Thanos PK
    Mol Pain; 2015 Aug; 11():52. PubMed ID: 26311517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Fatty Acid Binding Protein 5 Inhibitors Through Similarity-Based Screening.
    Zhou Y; Elmes MW; Sweeney JM; Joseph OM; Che J; Hsu HC; Li H; Deutsch DG; Ojima I; Kaczocha M; Rizzo RC
    Biochemistry; 2019 Oct; 58(42):4304-4316. PubMed ID: 31539229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incarvillateine produces antinociceptive and motor suppressive effects via adenosine receptor activation.
    Kim J; Bogdan DM; Elmes MW; Awwa M; Yan S; Che J; Lee G; Deutsch DG; Rizzo RC; Kaczocha M; Ojima I
    PLoS One; 2019; 14(6):e0218619. PubMed ID: 31237895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the fatty acid binding proteins disrupts multiple myeloma cell cycle progression and MYC signaling.
    Farrell M; Fairfield H; Karam M; D'Amico A; Murphy CS; Falank C; Pistofidi RS; Cao A; Marinac CR; Dragon JA; McGuinness L; Gartner CG; Iorio RD; Jachimowicz E; DeMambro V; Vary C; Reagan MR
    Elife; 2023 Mar; 12():. PubMed ID: 36880649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of binding affinity and docking of novel fatty acid-binding protein (FABP) ligands.
    Shinoda Y; Wang Y; Yamamoto T; Miyachi H; Fukunaga K
    J Pharmacol Sci; 2020 Aug; 143(4):264-271. PubMed ID: 32499096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of fatty acid-binding protein 5 and 7 on locomotor, anxiety and social behavior: Interaction with NMDA signaling.
    Khan A; Richardson B; Roeder N; Hamilton J; Marion M; Fearby N; White O; Owada Y; Kagawa Y; Thanos PK
    Neurosci Lett; 2024 Jul; 836():137862. PubMed ID: 38851448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanism with regard to the binding selectivity of inhibitors toward FABP5 and FABP7 explored by multiple short molecular dynamics simulations and free energy analyses.
    Chen J; Liu X; Zhang S; Chen J; Sun H; Zhang L; Zhang Q
    Phys Chem Chem Phys; 2020 Jan; 22(4):2262-2275. PubMed ID: 31917380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1,4-Dihydroquinazolin-3(2H)-yl benzamide derivatives as anti-inflammatory and analgesic agents with an improved gastric profile: Design, synthesis, COX-1/2 inhibitory activity and molecular docking study.
    Sakr A; Kothayer H; Ibrahim SM; Baraka MM; Rezq S
    Bioorg Chem; 2019 Mar; 84():76-86. PubMed ID: 30481648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of new dual FABP4/5 inhibitors based on a naphthalene-1-sulfonamide FABP4 inhibitor.
    He Y; Dou H; Gao D; Wang T; Zhang M; Wang H; Li Y
    Bioorg Med Chem; 2019 Oct; 27(19):115015. PubMed ID: 31420256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatty acid binding proteins are novel modulators of synaptic epoxyeicosatrienoic acid signaling in the brain.
    Glaser ST; Jayanetti K; Oubraim S; Hillowe A; Frank E; Jong J; Wang L; Wang H; Ojima I; Haj-Dahmane S; Kaczocha M
    Sci Rep; 2023 Sep; 13(1):15234. PubMed ID: 37709856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization of FABP3, 5 and 7 gene variants identified in schizophrenia and autism spectrum disorder and mouse behavioral studies.
    Shimamoto C; Ohnishi T; Maekawa M; Watanabe A; Ohba H; Arai R; Iwayama Y; Hisano Y; Toyota T; Toyoshima M; Suzuki K; Shirayama Y; Nakamura K; Mori N; Owada Y; Kobayashi T; Yoshikawa T
    Hum Mol Genet; 2014 Dec; 23(24):6495-511. PubMed ID: 25027319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and Preclinical Evaluation of a Novel Inhibitor of FABP5, ART26.12, Effective in Oxaliplatin-Induced Peripheral Neuropathy.
    Warren G; Osborn M; Tsantoulas C; David-Pereira A; Cohn D; Duffy P; Ruston L; Johnson C; Bradshaw H; Kaczocha M; Ojima I; Yates A; O'Sullivan SE
    J Pain; 2024 Jul; 25(7):104470. PubMed ID: 38232863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of Fabp7 and Fabp5 on postnatal hippocampal neurogenesis in the mouse.
    Matsumata M; Sakayori N; Maekawa M; Owada Y; Yoshikawa T; Osumi N
    Stem Cells; 2012 Jul; 30(7):1532-43. PubMed ID: 22581784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.